A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centre de Recherche Du Chum
Montreal, Quebec, Canada
- Jewish General Hospital
Montreal, Quebec, Canada
- Chu de Québec - Université Laval
Québec, Canada
- Highlands Oncology Group
Rogers, Arkansas, United States
- Florida Cancer Specialists
Sarasota, Florida, United States
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Tennessee Oncology, Pllc
Chattanooga, Tennessee, United States
- Tennessee Oncology
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Dec 2018
- Primary completion
- 30 Jun 2021
- Completion
- 31 Oct 2021
- Last update posted
- 24 Mar 2023
- Registered enrollment
- 69
- Registry id
- NCT03775850
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.